Thyroid Cancer Clinical Trial
Official title:
Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer
Thyroid cancer is the most prevalent endocrine malignancy.Papillary thyroid carcinomas and
follicular thyroid carcinomas account for 95% of all thyroid cancer cases. They are
clinically classified as well-differentiated thyroid carcinomas due to their biological
behavior resembling normal follicular cells and good responsiveness to surgery and
radioiodine therapy . However, they are usually curable when discovered at early stages, but
survival rates may be reduced from 100% in stages I and II to 50% at stage IV So,early
detection is the key for successful treatment and reduction of mortality.
pathological analysis by fine-needle aspiration biopsies has some limitations including
difficulty in sampling small tumors, inconclusive diagnosis in up to 35% of patients and
bleeding. Thus, biomarkers for diagnosis are needed.
Thyroid cancer is the most prevalent endocrine malignancy.Papillary thyroid carcinomas and
follicular thyroid carcinomas account for 95% of all thyroid cancer cases. They are
clinically classified as well-differentiated thyroid carcinomas due to their biological
behavior resembling normal follicular cells and good responsiveness to surgery and
radioiodine therapy . However, they are usually curable when discovered at early stages, but
survival rates may be reduced from 100% in stages I and II to 50% at stage IV So,early
detection is the key for successful treatment and reduction of mortality.
pathological analysis by fine-needle aspiration biopsies has some limitations including
difficulty in sampling small tumors, inconclusive diagnosis in up to 35% of patients and
bleeding. Thus, biomarkers for diagnosis are needed.
The concept of liquid biopsy was proposed in contrast to the traditional tissue biopsy which
is particularly important for solid tumor diagnosis. It refers to the process of detecting
genetic materials, using non-invasive method from blood or other body fluids.Long noncoding
RNAs (LncRNAs) have recently been demonstrated to participate in cancer progression.HOTAIR is
the type of non coding RNA that will be investigated for its ability to differentiate benign
from malignant thyroid nodule Midkine a basic heparin-binding growth factor of low molecular
weight, capable of exerting activities such as cell proliferation, cell migration,
angiogenesis and fibrinolysis. Midkine expression is closely related with progression of
tumor stage. If tumor tissues increase secretion of midkine, it becomes evident in serum.The
expression of midkine gene in human tumor cells may reflect tumor formation and give clues to
the biological behavior of neoplasms. Hence, the expression of midkine may serve as a tumor
marker for diagnosis and follow-up.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |